Blanqué Roland, Lepescheux Liên, Auberval Marielle, Minet Dominique, Merciris Didier, Cottereaux Céline, Clément-Lacroix Philippe, Delerive Philippe, Namour Florence
GALAPAGOS SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France.
BMC Musculoskelet Disord. 2014 Sep 3;15:291. doi: 10.1186/1471-2474-15-291.
Muscle wasting is a hallmark of many chronic conditions but also of aging and results in a progressive functional decline leading ultimately to disability. Androgens, such as testosterone were proposed as therapy to counteract muscle atrophy. However, this treatment is associated with potential cardiovascular and prostate cancer risks and therefore not acceptable for long-term treatment. Selective Androgen receptor modulators (SARM) are androgen receptor ligands that induce muscle anabolism while having reduced effects in reproductive tissues. Therefore, they represent an alternative to testosterone therapy. Our objective was to demonstrate the activity of SARM molecule (GLPG0492) on a immobilization muscle atrophy mouse model as compared to testosterone propionate (TP) and to identify putative biomarkers in the plasma compartment that might be related to muscle function and potentially translated into the clinical space.
GLPG0492, a non-steroidal SARM, was evaluated and compared to TP in a mouse model of hindlimb immobilization.
GLPG0492 treatment partially prevents immobilization-induced muscle atrophy with a trend to promote muscle fiber hypertrophy in a dose-dependent manner. Interestingly, GLPG0492 was found as efficacious as TP at reducing muscle loss while sparing reproductive tissues. Furthermore, gene expression studies performed on tibialis samples revealed that both GLPG0492 and TP were slowing down muscle loss by negatively interfering with major signaling pathways controlling muscle mass homeostasis. Finally, metabolomic profiling experiments using 1H-NMR led to the identification of a plasma GLPG0492 signature linked to the modulation of cellular bioenergetic processes.
Taken together, these results unveil the potential of GLPG0492, a non-steroidal SARM, as treatment for, at least, musculo-skeletal atrophy consecutive to coma, paralysis, or limb immobilization.
肌肉萎缩是许多慢性疾病的标志,也是衰老的标志,会导致功能逐渐衰退,最终导致残疾。雄激素,如睾酮,被提议作为对抗肌肉萎缩的疗法。然而,这种治疗存在潜在的心血管和前列腺癌风险,因此不适合长期治疗。选择性雄激素受体调节剂(SARM)是雄激素受体配体,可诱导肌肉合成代谢,同时对生殖组织的影响较小。因此,它们是睾酮治疗的替代方案。我们的目标是证明SARM分子(GLPG0492)在固定化肌肉萎缩小鼠模型中的活性,与丙酸睾酮(TP)相比,并确定血浆中可能与肌肉功能相关且可能转化到临床领域的潜在生物标志物。
在小鼠后肢固定模型中评估非甾体SARM GLPG0492,并与TP进行比较。
GLPG0492治疗部分预防了固定化诱导的肌肉萎缩,并有以剂量依赖方式促进肌纤维肥大的趋势。有趣的是,发现GLPG0492在减少肌肉损失同时保留生殖组织方面与TP一样有效。此外,对胫骨样本进行的基因表达研究表明,GLPG0492和TP都通过负面干扰控制肌肉质量稳态的主要信号通路来减缓肌肉损失。最后,使用1H-NMR的代谢组学分析实验导致鉴定出与细胞生物能量过程调节相关的血浆GLPG0492特征。
综上所述,这些结果揭示了非甾体SARM GLPG0492至少作为治疗因昏迷、瘫痪或肢体固定导致的肌肉骨骼萎缩的潜力。